


Policy questions for ACIP

- Should vaccination with **GSK RSVpreF3 vaccine** (120 μ g antigen + AS01E adjuvant, 1 dose IM), rather than no vaccine, be recommended in persons aged ≥ 65 years?
 - Should vaccination with **GSK RSVpreF3 vaccine** (120 μ g antigen + AS01E adjuvant, 1 dose IM), rather than no vaccine, be recommended in persons aged ≥ 60 years?
 - Should vaccination with **Pfizer bivalent RSVpreF vaccine** (120 μ g antigen, 1 dose IM), rather than no vaccine, be recommended in persons aged ≥ 65 years?
 - Should vaccination with **Pfizer bivalent RSVpreF vaccine** (120 μ g antigen, 1 dose IM), rather than no vaccine, be recommended in persons aged ≥ 60 years?
- 

For more information, contact CDC
1-800-CDC-INFO (232-4636)
TTY: 1-888-232-6348 www.cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

